Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.
Saved in:
| Title: | Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. |
|---|---|
| Authors: | Colca JR; Metabolic Solutions Development Company, Kalamazoo, Michigan, USA. jcolca@msdrx.com, VanderLugt JT, Adams WJ, Shashlo A, McDonald WG, Liang J, Zhou R, Orloff DG |
| Source: | Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2013 Apr; Vol. 93 (4), pp. 352-9. Date of Electronic Publication: 2013 Jan 18. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
